FMP
NASDAQ
22.47 USD
-0.59 (-2.63%)
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA
Healthcare
Biotechnology
https://www.sigilon.com
NASDAQ
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has ...
0001821323
US82657L1070
82657L107
100 Binney Street
617 336 7540
US
62
Dec 4, 2020
0001821323
NASDAQ
Biotechnology
Healthcare
82657L107
US82657L1070
US
22.47
4.11
120.68k
56.22M
-
3.77-28.0
0
-
-
-
-
-1.52
-
https://www.sigilon.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.